UA37259C2 - Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч - Google Patents

Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч

Info

Publication number
UA37259C2
UA37259C2 UA96104324A UA96104324A UA37259C2 UA 37259 C2 UA37259 C2 UA 37259C2 UA 96104324 A UA96104324 A UA 96104324A UA 96104324 A UA96104324 A UA 96104324A UA 37259 C2 UA37259 C2 UA 37259C2
Authority
UA
Ukraine
Prior art keywords
treatment
pharmaceutical compositions
active substance
compositions intended
metrorrhagia
Prior art date
Application number
UA96104324A
Other languages
English (en)
Russian (ru)
Inventor
Крістоф ХВАЛІШ
Кристоф ХВАЛИШ
Клаус ШТЕКЕМАНН
Original Assignee
Шерінг Актієнгезеллшафт
Шеринг Актиенгезеллшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шерінг Актієнгезеллшафт, Шеринг Актиенгезеллшафт filed Critical Шерінг Актієнгезеллшафт
Publication of UA37259C2 publication Critical patent/UA37259C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Застосування конкурентного антагоніста прогестерону як активної речовини для отримання лікарських засобів при лікуванні дисфункціональних маткових кровотеч.
UA96104324A 1995-02-02 1995-02-02 Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч UA37259C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (1)

Publication Number Publication Date
UA37259C2 true UA37259C2 (uk) 2001-05-15

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96104324A UA37259C2 (uk) 1995-02-02 1995-02-02 Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч

Country Status (20)

Country Link
US (1) US6451780B1 (uk)
EP (1) EP0806952B1 (uk)
JP (1) JPH10512889A (uk)
KR (1) KR100370908B1 (uk)
AT (1) ATE235907T1 (uk)
AU (1) AU714959B2 (uk)
CA (1) CA2186953C (uk)
DE (1) DE59510626D1 (uk)
DK (1) DK0806952T3 (uk)
ES (1) ES2196063T3 (uk)
FI (1) FI117850B (uk)
HU (1) HU226276B1 (uk)
MX (1) MX9603889A (uk)
NO (1) NO964155D0 (uk)
NZ (1) NZ287024A (uk)
PL (1) PL316533A1 (uk)
PT (1) PT806952E (uk)
SK (1) SK282570B6 (uk)
UA (1) UA37259C2 (uk)
WO (1) WO1996023503A1 (uk)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ATE375160T1 (de) 1999-08-31 2007-10-15 Bayer Schering Pharma Ag Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
WO2005120432A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
HUE029397T2 (en) * 2007-04-20 2017-03-28 Preglem Sa Selective progesterone modulators for treating uterine bleeding
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
EP0806952A1 (de) 1997-11-19
AU714959B2 (en) 2000-01-13
PT806952E (pt) 2003-08-29
NZ287024A (en) 2001-03-30
HU226276B1 (en) 2008-07-28
KR970704451A (ko) 1997-09-06
PL316533A1 (en) 1997-01-20
NO964155L (no) 1996-10-01
CA2186953A1 (en) 1996-08-08
FI117850B (fi) 2007-03-30
DK0806952T3 (da) 2003-06-16
WO1996023503A1 (de) 1996-08-08
ATE235907T1 (de) 2003-04-15
HU9602668D0 (en) 1996-11-28
DE59510626D1 (de) 2003-05-08
FI963049A0 (fi) 1996-08-01
NO964155D0 (no) 1996-10-01
FI963049A (fi) 1996-10-01
EP0806952B1 (de) 2003-04-02
SK121996A3 (en) 1997-05-07
MX9603889A (es) 1997-04-30
ES2196063T3 (es) 2003-12-16
KR100370908B1 (ko) 2003-04-10
US6451780B1 (en) 2002-09-17
AU2561195A (en) 1996-08-21
SK282570B6 (sk) 2002-10-08
CA2186953C (en) 2009-11-10
JPH10512889A (ja) 1998-12-08
HUT75930A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
IL140930A0 (en) Compounds and compositions for delivering active agents
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
HK1021539A1 (en) Androstene derivatives.
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
NO910874D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
IE883402L (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
HUP9902723A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating migraine pain
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
ITMI922216A0 (it) Nitrobenzoilalanine procedimento per la loro preparazione loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono